問卷

TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Thoracic Medicine

Division of Thoracic Surgery

Division of General Internal Medicine

更新時間:2023-09-19

王圳華Wang, Chun-Hua
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 10 個月

篩選

List

41Cases

2005-06-01 - 2007-01-01

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2025-10-31 - 2029-06-26

Phase II

Not yet recruiting
A Phase 2b Randomized, Double-blind, Placebo-controlled, Parallel-Group Study to Assess Efficacy and Safety of Verekitug (UPB-101) in Participants with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
  • Condition/Disease

    Moderate-to-severe COPD

  • Test Drug

    Injection

Participate Sites
8Sites

Not yet recruiting8Sites

2021-07-27 - 2026-09-30

Phase II

Active
xxxxxx
  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
13Sites

Recruiting13Sites

2011-09-01 - 2018-06-30

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2008-10-01 - 2010-12-31

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2011-03-01 - 2015-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2015-08-01 - 2017-12-31

Phase III

A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of dupilumab in patients with persistent asthma
  • Condition/Disease

    persistent asthma

  • Test Drug

    dupilumab

Participate Sites
12Sites

Terminated10Sites

2008-10-01 - 2012-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated1Sites

Suspended1Sites

2011-09-29 - 2013-12-16

Phase II

A Phase 1-2 trial of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer
  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    MM-121(SAR256212)

Participate Sites
6Sites

Terminated6Sites

2010-04-01 - 2012-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

1 2 3 4 5